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Thank you for submitting your manuscript to The EMBO Journal. I am very sorry for the delay in getting back to you with a decision. I have now received the comments from the two referees and I am afraid that the overall opinion is not positive.
The referees appreciate that the analysis is well done, but they are also not convinced that the advance and insight provided is sufficient to consider publication here. The referees find that the analysis remains too descriptive and that we gain too limited new mechanistic insight. Given the referee comments and as we require strong support from referees for consideration here I can unfortunately not offer to consider publication here.
Given the interest in the topic I have discussed the manuscript and the back-to-back submission from The Mandekow lab with my colleague Esther Schnapp from EMBO Reports. EMBO Reports is interested in considering both manuscripts for publication in EMBO Reports and will work with the two referee reports on hand. The specific concerns raised by referee #1 would have to be sorted out. Referee #2 brings up the issue of neuronal loss and I don't know if you have any data on hand to address this issue. If you are interested in transferring to EMBO Reports, I would suggest that you contact Esther Schnapp at esther.schnapp@embo.org to discuss this option further with her.
For the EMBO Journal. I am sorry that I can't be more positive on this occasion, but I hope that you will consider the EMBO Reports option.
REFEREE REPORTS Referee #1:
Maeda et al report on the characterization of neuronal A152T tau expression in inducible transgenic mice and compare this line to wild type human tau. Though there are some interesting aspects to this manuscript, the lack of biochemical data and the overreliance solely on IHC data makes some of the conclusion a bit speculative. There is through behavioral characterization of these mice, as well as survey of other phenotypes such as susceptibility to seizure and some electrophysiological aspects. Figure 1 . The Blots are cut off. Are there any high molecular weight tau species on these gels? The blots are also quite manipulated in image. Figure 2 . Quality of images here could be improved (might just be the upload).
The GFAP data showing differences by immunoreactivty is hard to believe it's a subtle difference it would b good to back this up with Western blots. What about microglial staining? Figure 4 . Tau has a long half-life I am little surprised that two months of Dox truly leads to apparently almost no human ta as demonstrated by IHC. Again it would be nice to back this up with Westerns. Same issue with GFAP as before (though the difference here is larger, so more believable that it would be picked up by IHC)
Overall the lack of supporting biochemical studies on solubility of tau in these mice limit some of the inferences that can be made.
In isolation this manuscript is largely descriptive of a new tau transgenic model, and though it will be of interest to the field, it largely lacks a real mechanistic punch. Clearly this will be an important tool for the filed, but little new insight into why this particular mutations is different from other disease linked tau mutations is provided.
Referee #2:
This is an extremely well-assembled and well-performed study showing the consequences of transgenic over-expression of the A152T tau variant in mice. Of particular interest is the comparison between wildtype and the A152T variant, as well as the use of tet-inducible expression. The evaluation of this particular mutant in mice is new, and the studies are well-done. But it is unclear how this model provides new insights into the mechanism of tau-mediated neurodegeneration over other existing models. There are also some concerns about the necessity of some of the data. In particular, Figure 2 seems unnecessary and without an explanation as to why A152T would produce more protein, it adds little value. The behavioral and electrophysiological changes caused by A152T are fairly subtle, and only a few assays showed differences between WT and 152T tau as expected. Perhaps the most intriguing aspect of the study is that these mice were crossed to J20 APP mice and synergy was shown when these two proteins were together with regard to survival and neuronal activity. This seems like the beginning of some interesting studies, comparing the effects of A152T and WT tau on APP associated morbidities, but it is very preliminary. Other studies looking at the effects of APP on tau pathology or even tau on Aß production could be very interesting.
So overall, this is a very well done paper, but the resulting phenotypes are unremarkable and the mechanistic insights about the differences between wildtype and this variant are not clear. The lack of progressive neurodegeneration or even silver positive tau makes this a model of tau overexpression with limited utility relative to what is already available. The crossed animals are interesting, but the data presented is limited and critical questions left unanswered. The fact that there is some synergy between APP and tau is interesting and should be explored further. If the authors showed that this variant does cause progressive neuronal loss to a greater extent than other variants or could provide a mechanism for how A152T becomes more toxic or pathogenic than wildtype to a stimulus such as APP, then there would be more enthusiasm.
TRANSFERRED TO EMBO REPORTS 1st Editorial Decision 06 October 2015
Thank you for the transfer of your research manuscript with referee comments to EMBO reports. As discussed, we can consider a revised manuscript for publication, and additional insight into mechanism will not be required for EMBO reports.
However, please address the referee concerns to the best of your abilities in a complete point-bypoint response and also provide data on neuronal loss in your tau mutant mice.
Acceptance of the manuscript will depend on a positive outcome of a second round of review. It is EMBO reports policy to allow a single round of revision only and acceptance or rejection of the manuscript will therefore depend on the completeness of your responses included in the next, final version of the manuscript.
Revised manuscripts should be submitted within three months of a request for revision; they will otherwise be treated as new submissions. Given your 10 main figures, we will publish your manuscript as a regular research article. Please also change the reference style to the numbered EMBO reports style.
We now strongly encourage the publication of original source data with the aim of making primary data more accessible and transparent to the reader. The source data will be published in a separate source data file online along with the accepted manuscript and will be linked to the relevant figure.
If you would like to use this opportunity, please submit the source data (for example scans of entire gels or blots, data points of graphs in an excel sheet, additional images, etc.) of your key experiments together with the revised manuscript. Please include size markers for scans of entire gels, label the scans with figure and panel number, and send one PDF file per figure or per figure panel.
I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision. Shown below for review only are the top parts of the western blots in question. No high-molecular-weight tau species were seen on these blots. We do not understand the referee's second statement. The images were directly imported from the LiCor Odyssey blot reader into Photoshop as they were. Besides being thresholded equally across all lanes to optimize the visibility of the bands and being cropped above and below relevant bands to save space, they were not manipulated in any way. Notably, the thresholding process is automated, routinely done, and does not affect the measured signal intensities, which were quantitated automatically by the blot reader.
Figure 2. Quality of images here could be improved (might just be the upload). The GFAP data showing differences by immunoreactivity is hard to believe it's a subtle difference it would be good to back this up with Western blots. What about microglial staining?
We assume the referee was actually referring to Figure 3 here. If so, we agree with the first statement, and we have improved the quality of the images in this figure.
The methods we used to quantify the activation state of astrocytes-which are rigorous, well accepted, and widely used in the field (e.g., Bailey et al, 2013; Higuchi et al, 2002 )-revealed statistically significant differences between hTau-A152T mice and controls. The concept of "believing" or "not believing" such differences when they have been identified by rigorous statistical tests is perplexing to us. GFAP levels measured by immunohistochemistry are tightly correlated with those measured by western blot analysis (Si et al, 2004) . In fact, immunohistochemistry is more sensitive and informative than western blotting because it can detect increases in GFAP expression even in subfields of brain regions. Therefore, it is unlikely that the proposed western blot analysis would add much to our study.
As for microglial staining, the referee may have overlooked Supplemental Figure S7B (now Expanded View 3P), which showed no difference in microglial Iba1 staining between hTau-A152T mice and controls.
Figure 4. Tau has a long half-life I am little surprised that two months of Dox truly leads to apparently almost no human tau as demonstrated by IHC. Again it would be nice to back this up with Westerns. Same issue with GFAP as before (though the difference here is larger, so more believable that it would be picked up by IHC)
In the revised manuscript, we now cite a study that showed that intracerebroventricular infusion of antisense oligonucleotides against tau reduces endogenous tau levels in the brains of wildtype mice within 4 weeks (Devos et al, 2013) . It is therefore not surprising that we were able to eliminate hTau from brain in our models by suppressing transgene expression for 2 months, particularly because these models show no evidence of tau aggregation (see below).
To address the referee's concerns, we assessed the solubility of tau in hTau-WT and hTau-A152T mice by western blot analysis. As documented in the newly added Expanded View 4K-P, this analysis detected insoluble tau in PS19 mice, which served as a positive control, but not in hTau-WT or hTau-A152T mice. These findings are consistent with the results we obtained by Gallyas silver staining of brain sections. Dense neuronal labeling with this method is widely accepted as a reliable indicator of insoluble tau species (e.g., Gallyas, 1971; Polydoro et al, 2013; Sun et al, 2002) . We detected such labeling in rTg4510 mice, which are known to accumulate insoluble tau, but not in hTau-A152T mice (Expanded View 4A-J). hTau-A152T mice showed only faint cortical staining suggestive of neuronal injury, but no neuronal labeling at all in the hippocampus. We therefore conclude that the A152T variant does not enhance tau aggregation, consistent with the results of an in vitro tau aggregation assay (Coppola et al, 2012) . We respectfully disagree with this evaluation. The A152T substitution differs from previously studied MAPT mutations because it has been linked not only to FTLD, but also to AD. Our manuscript provides the following novel insights into its pathomechanisms:
In isolation this
• The A152T substitution increases the protein/mRNA ratio of hTau, which could promote hTau accumulation in neurons.
• Neuronal expression of hTau-A152T in transgenic mice leads to the intraneuronal accumulation of abnormal soluble tau species, particularly in the mossy fiber pathway of the hippocampus.
• It also causes network hyperexcitability, epileptiform activity, and age-dependent behavioral deficits.
• hTau-A152T expression sensitizes mice to the adverse effects of Aβ accumulation in the brain, which helps explain why A152T increases risk for AD, unlike other FTLD-linked mutations.
Referee 2

This is an extremely well-assembled and well-performed study showing the consequences of transgenic over-expression of the A152T tau variant in mice. Of particular interest is the comparison between wildtype and the A152T variant, as well as the use of tet-inducible expression. The evaluation of this particular mutant in mice is new, and the studies are well-done. But it is unclear how this model provides new insights into the mechanism of tau-mediated neurodegeneration over other existing models.
The A152T substitution differs from previously studied MAPT mutations because it has been linked not only to FTLD, but also to AD. As stated above in response to Referee 1, our manuscript provides the following novel insights into its pathomechanisms:
• hTau-A152T expression sensitizes mice to the adverse effects of Aβ accumulation in brain, which helps explain why A152T increases risk for AD, unlike other FTLD-linked mutations.
There are also some concerns about the necessity of some of the data. In particular, Figure 2 seems unnecessary and without an explanation as to why A152T would produce more protein, it adds little value.
The increased protein/mRNA ratio is a novel aspect of the A152T tau variant and helps explain why it increases the risk for diverse tauopathies, as we discussed in the paper. Excluding this interesting finding would weaken our manuscript. We agree that determining how the A152T substitution increases the tau protein/mRNA ratio is an important objective, but we consider this quest beyond the scope of the current manuscript. Indeed, the current study provides the first evidence that a tau variant can enhance APP/Aβ-dependent network dysfunction. Identifying the exact convergence point between hTau-A152T and APP/Aβ will require a much larger body of work than could be presented in the current paper, which is substantive as it is (after the revision: 11 main figures + 5 expanded views = 16 figures in total). Furthermore, because we needed to generate 282 pups in order to obtain 8 viable triply transgenic hAPP-J9 / TRE-hTau-A152T / CaMKII-tTA mice, the proposed assessment of potential tau effects on Aβ production would take a long time. In regards to the referee's other suggestion, several groups have already demonstrated that APP/Aβ can worsen tau pathology (e.g., Götz et al, 2001) . To address the referee's suggestion, we assessed neuronal loss in hTau transgenic mice by counting NeuN-positive cells. Neuronal loss was evident only in hTau-A152T mice at advanced age (new Fig. 8A -C) when such mice also had cognitive impairments ( Fig. 6 and Expanded View 5B-G). In parallel, we confirmed by biochemical analysis our previous findings that hTau-WT and hTau-A152T mice do not have tau aggregates even at old age, whereas tau aggregates were readily detectable in PS19 mice, a positive control that expresses FTDP-17 mutant hTau (EV4K-P). Taken together, these findings provide interesting new insights into the pathogenic potential of soluble tau and-importantly-raise the possibility that tau aggregation inhibitors may not be enough to block tau pathogenesis.
We also feel compelled to emphasize that what matters the most to patients with FTLD or AD and their families are the cognitive and behavioral alterations these disorder cause. We therefore consider it remarkable that hTau-A152T mice developed age-dependent cognitive and behavioral alterations, whereas expression-matched hTau-WT mice did not. We observed several other functional abnormalities in both models, highlighting the pathogenic potential of overall tau accumulation, which A152T could promote by increasing tau protein/mRNA ratios, as well as the importance of including hTau-WT mice as controls. We consider it important to alert the field to these findings.
Other FTLD-linked tau mutations cause tauopathy with high penetrance, whereas the A152T substitution primarily acts as a risk factor that increases susceptibility to diverse tauopathies (Coppola et al, 2012; Labbe et al, 2015) . It is therefore interesting that the phenotype of hTau-A152T mice was markedly worsened by the expression of a co-pathogen (hAPP/Aβ). Although new discoveries often raise more questions than they answer, we think that our demonstration of functional synergism between hTau-A152T and hAPP/Aβ is important and noteworthy. It also nicely illustrates that the new model we created can be used to explore how this tau variant increases the risk for AD and other tauopathies. However, as stated above, to find out the exact convergence point between hTau-A152T and APP/Aβ will require a much larger body of work that is beyond the scope of the current study. This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation. a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
In the pink boxes below, provide the page number(s) of the manuscript draft or figure legend(s) where the information can be located. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable).
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner. the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND ê
For biochemical analysis, we estimated the sample sizes based on pilot studies. For behavioral studies, we estimated the sample sizes based on power calculations from another AD model. The chosen sample sizes were confirmed to be adequate in pilot studies. In addition, we validated our findings in independent cohorts. All of the experiments described in this study are animal experiments. We estimated the sample sizes based on power calculations from another AD model or from pilot studies.
None of the animals were excluded in any of our experiments, unless we encountered a technical failure such as equipment failure.
All samples were randomly selected to avoid the effects of subjective bias. Mice were selected only based on the genotypes, but not based on any other readouts.
The selection of animals was random. The randomization and blinding procedures for behavioral tests are described in the method section of the manuscript.
The mice for the studies were randomly selected. To blind the experimentalist during the behavioral tests, another investigator assigned random numbers to individual mice and obscured the genotypes. The hTau--A152T mice had slightly lower body weights; however, that information was not disclosed to the experimentalist to avoid any subjective bias.
For ELISA and qRT--PCR, and during behavioral testing, the experimentalists were blinded to mouse genotype. We didn't use blinding for the Western blot analysis in order to align the samples according to the genotype.
definitions of statistical methods and measures:
Journal Submitted to: EMBO Reports Corresponding Author Name: Lennart Mucke
C--Reagents
The statistical methods were justified based on the criteria that we developed in collaboration with experienced biostatisticians in the Gladstone Biostatistics Core. Criteria can be found in the method section of the manuscript.
Normality was assessed with the Shapiro--Wilk test for datasets with sample size <10 per group. For N>=10, parametric tests were used without assessing normality, because normal distribution is not required for use of parametric tests for N>=10 .
An estimation of variation was included in our power calculations.
Variances were assessed with the F--test (two groups) or Bartlett's test (more than two groups). When the variance was different between groups, we applied Welch's correction.
